Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking for Charity - 2006 -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (333)	2/23/2006 6:13:21 PM
From: IRWIN JAMES FRANKEL	Respond to of 592

STXS - After hours they got clipped, deservedly. Backlog did show some sign of life rising from $23M (3Q) to $26.1M (4Q). My focus is on backlog. I think that will give us a signal when to buy. Niobe is revolutionary tech, IMO. That view is shared by surgeons that have used it. ij

To: Arthur Radley who wrote (333)	2/24/2006 9:25:52 AM
From: dr.praveen	Read Replies (1) \| Respond to of 592

STXS/HSBC upgrades Stereotaxis to Overweight from Neutral and raises their target to $16 from $14.50. Firm expects the stock to trade below $12 as short-term investors hoping for near-term upside may be disappointed with the one Niobe system sale in 4Q05 and 2006 revenue guidance that was "heavily back end loaded." However, they believe STXS is well positioned to recognize at least 20 Niobe system sales in 2006; increasing their annual estimates for recurring revenue per installed Niobe system for 2006 to 2009. Regards, Praveen